白细胞介素2和α干扰素用于转移性黑色素瘤患者的II期研究最终报告。
Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma.
作者信息
Kruit W H, Goey S H, Calabresi F, Lindemann A, Stahel R A, Poliwoda H, Osterwalder B, Stoter G
机构信息
Department of Medical Oncology, Rotterdam Cancer Institute, The Netherlands.
出版信息
Br J Cancer. 1995 Jun;71(6):1319-21. doi: 10.1038/bjc.1995.256.
Abstract
Fifty-seven patients with metastatic melanoma were treated with interleukin 2 (IL-2) 7.8 MIU m-2 day-1 as a continuous infusion for 4 days combined with interferon alpha (IFN-alpha) 6 MIU m-2 day-1 subcutaneously on days 1 and 4. The cycle was repeated every 2 weeks for a maximum number of 13 cycles. Of the 51 evaluable patients, one (2%) achieved a complete and seven (14%) a partial response (total response rate 16%; CI 7-29%). Median time to progression and median survival were 2.5 and 11.3 months respectively. This regimen of IL-2 and IFN-alpha appeared to be only moderately active.
摘要
57例转移性黑色素瘤患者接受治疗，白细胞介素2（IL-2）以7.8 MIU/m²/天持续输注4天，并在第1天和第4天皮下注射干扰素α（IFN-α）6 MIU/m²/天。每2周重复1个周期，最多进行13个周期。在51例可评估的患者中，1例（2%）达到完全缓解，7例（14%）达到部分缓解（总缓解率16%；可信区间7%-29%）。中位疾病进展时间和中位生存期分别为2.5个月和11.3个月。这种IL-2和IFN-α方案似乎只有中度活性。
相似文献
1
Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma.白细胞介素2和α干扰素用于转移性黑色素瘤患者的II期研究最终报告。
Br J Cancer. 1995 Jun;71(6):1319-21. doi: 10.1038/bjc.1995.256.
2
Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.在转移性黑色素瘤患者中进行的BCDT[卡莫司汀（BCNU）、顺铂、达卡巴嗪（DTIC）和他莫昔芬]联合或不联合α干扰素（IFN-α）及白细胞介素（IL-2）的随机II期试验。
Br J Cancer. 1998 Apr;77(8):1280-6. doi: 10.1038/bjc.1998.214.
3
Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.白细胞介素-2与淋巴因子激活的杀伤细胞联合免疫调节剂量化疗并序贯使用α-2a干扰素治疗转移性黑色素瘤和肾细胞癌患者的初步研究。
J Natl Cancer Inst. 1992 Jun 17;84(12):929-37. doi: 10.1093/jnci/84.12.929.
4
Clinical experience with the combined use of recombinant interleukin-2 (IL2) and interferon alfa-2a (IFN alpha) in metastatic melanoma.重组白细胞介素-2（IL2）与干扰素α-2a（IFNα）联合用于转移性黑色素瘤的临床经验。
Br J Haematol. 1991 Oct;79 Suppl 1:84-6. doi: 10.1111/j.1365-2141.1991.tb08128.x.
5
Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.白细胞介素-2、α干扰素和5-氟尿嘧啶免疫化疗治疗进展性转移性肾细胞癌：一项多中心II期研究。荷兰免疫治疗工作组
Br J Cancer. 2000 Feb;82(4):772-6. doi: 10.1054/bjoc.1999.0997.
6
Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma.用于治疗转移性黑色素瘤的门诊化疗免疫治疗方案的更新分析。
Cancer J Sci Am. 1997 Dec;3 Suppl 1:S29-34.
7
Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma.顺铂、白细胞介素-2和干扰素α-2a序贯化学免疫疗法治疗转移性黑色素瘤。
J Clin Oncol. 1993 Nov;11(11):2173-80. doi: 10.1200/JCO.1993.11.11.2173.
8
Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.达卡巴嗪、顺铂和α-2b干扰素联合或不联合白细胞介素-2用于转移性黑色素瘤：欧洲癌症研究与治疗组织黑色素瘤小组的一项随机III期试验（18951）
J Clin Oncol. 2005 Sep 20;23(27):6747-55. doi: 10.1200/JCO.2005.03.202.
9
Clinical results using biochemotherapy as a standard of care in advanced melanoma.
Melanoma Res. 2002 Aug;12(4):381-7. doi: 10.1097/00008390-200208000-00011.
10
Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.在进展期转移性肾细胞癌患者中采用皮下注射GM-CSF、低剂量IL-2和IFN-α进行同步免疫治疗。
Br J Cancer. 2003 May 6;88(9):1346-51. doi: 10.1038/sj.bjc.6600915.
引用本文的文献
1
Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.大剂量推注白细胞介素2和干扰素α两种给药方案治疗转移性黑色素瘤的剂量疗效研究
Br J Cancer. 1996 Sep;74(6):951-5. doi: 10.1038/bjc.1996.463.
本文引用的文献
1
Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.高剂量白细胞介素-2单独或联合淋巴因子激活的杀伤细胞治疗晚期癌症患者的前瞻性随机试验。
J Natl Cancer Inst. 1993 Apr 21;85(8):622-32. doi: 10.1093/jnci/85.8.622.
2
Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience.788例癌症患者住院持续输注白细胞介素-2。国家生物治疗研究组的经验。
Cancer. 1993 Apr 1;71(7):2358-70. doi: 10.1002/1097-0142(19930401)71:7<2358::aid-cncr2820710730>3.0.co;2-m.
3
Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma.高剂量白细胞介素-2单独或联合干扰素α-2a治疗晚期黑色素瘤患者的随机III期试验。
J Clin Oncol. 1993 Oct;11(10):1969-77. doi: 10.1200/JCO.1993.11.10.1969.
4
Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.采用LAK细胞和重组白细胞介素-2对已形成的肺转移瘤进行过继性免疫治疗。
Science. 1984 Sep 28;225(4669):1487-9. doi: 10.1126/science.6332379.
5
Treatment of metastatic malignant melanoma with recombinant interferon alpha 2.用重组干扰素α2治疗转移性恶性黑色素瘤。
Immunobiology. 1986 Sep;172(3-5):275-82. doi: 10.1016/S0171-2985(86)80109-7.
6
In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells.α干扰素与白细胞介素-2联合用药在小鼠模型中的体内抗肿瘤活性。疗效与诱导类似自然杀伤细胞的细胞毒性细胞之间的相关性。
Int J Cancer. 1987 Sep 15;40(3):365-71. doi: 10.1002/ijc.2910400314.
7
8
Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study.重组人白细胞介素-2与重组干扰素α-2A联合用于癌症患者的治疗：一项I期研究。
J Clin Oncol. 1989 Nov;7(11):1726-32. doi: 10.1200/JCO.1989.7.11.1726.
9
Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.白细胞介素2与α干扰素的I期临床试验：毒性及免疫效应
Cancer Res. 1989 Nov 15;49(22):6432-6.
10
Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.白细胞介素-2与α-干扰素联合治疗晚期癌症患者。
J Clin Oncol. 1989 Dec;7(12):1863-74. doi: 10.1200/JCO.1989.7.12.1863.
Zotero 插件